Intravenous immune globulin ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 256 | Muscle glycogenosis | 1 |
256. Muscle glycogenosis
Clinical trials : 180 / Drugs : 153 - (DrugBank : 30) / Drug target genes : 31 - Drug target pathways : 134
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02525172 (ClinicalTrials.gov) | August 2015 | 10/8/2015 | Immune Modulation Therapy for Pompe Disease | Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients | Pompe Disease | Drug: Rituximab;Drug: intravenous immune globulin;Drug: Bortezomib;Drug: Methotrexate | National Taiwan University Hospital | NULL | Recruiting | N/A | N/A | Both | 8 | Phase 4 | Taiwan |